Govt revises NLEM: Slashes prices of 39 commonly used medicines

Revising the 'National List of Essential Medicines', the central govenrment has slashed the prices of 39 commonly used drugs.

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
IANS New Delhi
2 min read Last Updated : Sep 04 2021 | 1:06 PM IST

Revising the 'National List of Essential Medicines' (NLEM), the central govenrment has slashed the prices of 39 commonly used drugs.

The prices were slashed for the anti-cancer, anti-diabetes, antiviral, antibacterial, antiretroviral, anti-TB drugs, and also for some that are used in Covid treatment.

The experts working on the NLEM list have deleted 16 odd drugs from the list.

The Indian Council of Medical Research (ICMR) has been working for a long time to extend price control on medicines.

The commonly used drugs, which were brought under the price cap includes Teneligliptin -- an anti diabetes drug, popular anti-TB drugs, Ivermectin -- used in Covid treatment, Rotavirus vaccine, among others.

The government had begun an exercise for the revision of the NLEM, which was notified in 2015 and implemented in 2016.

It is a departure from the present practice, where all essential medicines automatically go under price control.

The Standing National Committee on Medicines was tasked with preparing the list of which medicines should be available in adequate numbers and assured quantity.

The committee headed by Balram Bhargava, Secretary in the Department of Health Research and Director General of the ICMR, send the list to a second committee comprising senior officials from NITI Aayog, Health Secretary and Secretary in the Department of Pharmaceuticals, which decides on which drugs are to be put under the price cap.

--IANS

avr/shs/in

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :NLEMMedicines

First Published: Sep 04 2021 | 1:06 PM IST

Next Story